- Home
- EXAS vs CPB Comparison
EXAS vs CPB Comparison
Compare EXAS & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- CPB
- Stock Information
- Founded
- EXAS 1995
- CPB 1869
- Country
- EXAS United States
- CPB United States
- Employees
- EXAS N/A
- CPB N/A
- Industry
- EXAS Medical Specialities
- CPB Packaged Foods
- Sector
- EXAS Health Care
- CPB Consumer Staples
- Exchange
- EXAS Nasdaq
- CPB Nasdaq
- Market Cap
- EXAS 10.6B
- CPB 9.2B
- IPO Year
- EXAS N/A
- CPB N/A
- Fundamental
- Price
- EXAS $57.01
- CPB $31.27
- Analyst Decision
- EXAS Strong Buy
- CPB Hold
- Analyst Count
- EXAS 21
- CPB 16
- Target Price
- EXAS $67.86
- CPB $34.20
- AVG Volume (30 Days)
- EXAS 2.3M
- CPB 5.8M
- Earning Date
- EXAS 11-04-2025
- CPB 09-03-2025
- Dividend Yield
- EXAS N/A
- CPB 4.88%
- EPS Growth
- EXAS N/A
- CPB 6.35
- EPS
- EXAS N/A
- CPB 2.01
- Revenue
- EXAS $2,939,949,000.00
- CPB $10,253,000,000.00
- Revenue This Year
- EXAS $16.68
- CPB N/A
- Revenue Next Year
- EXAS $12.08
- CPB $1.13
- P/E Ratio
- EXAS N/A
- CPB $15.90
- Revenue Growth
- EXAS 12.55
- CPB 6.40
- 52 Week Low
- EXAS $38.81
- CPB $29.39
- 52 Week High
- EXAS $72.83
- CPB $49.11
- Technical
- Relative Strength Index (RSI)
- EXAS 68.53
- CPB 40.98
- Support Level
- EXAS $52.85
- CPB $31.25
- Resistance Level
- EXAS $54.74
- CPB $32.09
- Average True Range (ATR)
- EXAS 1.40
- CPB 0.86
- MACD
- EXAS 0.17
- CPB -0.21
- Stochastic Oscillator
- EXAS 93.39
- CPB 12.72
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About CPB Campbell Soup Company
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024 (July year-end), snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.